Search
Citations & References (7)
Invitrogen™
ViraPower™ Adenoviral Gateway™ Expression Kit
Invitrogen’s ViraPower™ Adenoviral Expression System facilitates highly efficient, in vitro or in vivo delivery of a target gene to dividingRead more
| Catalog Number | Quantity |
|---|---|
| K493000 | 1 kit |
Catalog number K493000
Price (MXN)
-
Quantity:
1 kit
Invitrogen’s ViraPower™ Adenoviral Expression System facilitates highly efficient, in vitro or in vivo delivery of a target gene to dividing and non-dividing mammalian cells using a replication-incompetent adenovirus. ViraPower™ Adenoviral Expression System takes advantage of the Gateway™ Recombination Cloning Technology to simplify cloning, which greatly enhances the efficiency of generating high-titer, recombinant adenovirus. This kit contains the pAd⁄CMV⁄V5-DEST Gateway™-adapted adenoviral vector enabling high level protein expression from human cytomegalovirus (CMV) immediate-early enhancer⁄promoter) as well as the 293A cell line.
Key advantages:
• Produce high titer adenoviral stocks up to 1 x 1011 pfu⁄ml in concentrated preparations
• High efficiency and rapid Gateway™ Recombination Cloning bypasses inefficient homologous recombination in human or bacterial cells
• Efficient delivery of the gene of interest to actively dividing and non-dividing mammalian cells in culture or in vivo
• Amenable for high-throughput applications or library transfer applications
• Produces of a replication-incompetent virus that enhances the biosafety of the system and its use as a gene delivery vehicle
Key advantages:
• Produce high titer adenoviral stocks up to 1 x 1011 pfu⁄ml in concentrated preparations
• High efficiency and rapid Gateway™ Recombination Cloning bypasses inefficient homologous recombination in human or bacterial cells
• Efficient delivery of the gene of interest to actively dividing and non-dividing mammalian cells in culture or in vivo
• Amenable for high-throughput applications or library transfer applications
• Produces of a replication-incompetent virus that enhances the biosafety of the system and its use as a gene delivery vehicle
For Research Use Only. Not for use in diagnostic procedures.
Specifications
Constitutive or Inducible SystemConstitutive
Delivery TypeAdenoviral
For Use With (Application)Viral Expression
Product TypeAdenoviral Expression Kit
Quantity1 kit
VectorpAd
Cloning MethodGateway
Product LineGateway, ViraPower
PromoterCMV
Protein TagV5 Epitope Tag
Unit SizeEach
Contents & Storage
pAd⁄CMV⁄V5-DEST Gateway™ Vector: store at -20°C;.
293A Cells: store in liquid nitrogen.
Guaranteed stable for 6 months when properly stored.
293A Cells: store in liquid nitrogen.
Guaranteed stable for 6 months when properly stored.
Frequently asked questions (FAQs)
Can I perform the single-step protocol for the BP/LR Clonase reaction using BP Clonase enzyme and LR Clonase enzyme instead of BP Clonase II enzyme and LR Clonase II enzyme?
Do you have a recommended single-step protocol for BP/LR recombination?
How can I move my gene of interest from a Gateway-adapted expression clone to a new Destination vector as I have lost the entry clone?
Can I purchase the 5X LR Clonase buffer or 5X BP Clonase buffer separately?
Do you offer Gateway vectors for expression in plants?
Citations & References (7)
Citations & References
Abstract
The receptor for parathyroid hormone and parathyroid hormone-related peptide is hydrolyzed and its signaling properties are altered by directly binding the calpain small subunit.
Journal:Endocrinology
PubMed ID:15691895
'We show calcium-dependent, direct binding between the N-terminal portion of the PTH/PTHrP receptor (PTH1R) C-terminal intracellular tail and the calpain small subunit. Binding requires, but may not be limited to, amino acids W474, S475, and W477. The wild-type, full-length rat (r) PTH1R, but not rPTH1R with W474A/W477A substitutions, copurifies with
p116Rip targets myosin phosphatase to the actin cytoskeleton and is essential for RhoA/ROCK-regulated neuritogenesis.
Journal:Mol Biol Cell
PubMed ID:15469989
Activation of the RhoA-Rho kinase (ROCK) pathway stimulates actomyosin-driven contractility in many cell systems, largely through ROCK-mediated inhibition of myosin II light chain phosphatase. In neuronal cells, the RhoA-ROCK-actomyosin pathway signals cell rounding, growth cone collapse, and neurite retraction; conversely, inhibition of RhoA/ROCK promotes cell spreading and neurite outgrowth. The
Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs.
Journal:Infect Immun
PubMed ID:16113296
Interleukin-23 (IL-23) is a heterodimeric cytokine that shares IL-12 p40 but contains a unique p19 subunit similar to IL-12 p35. Previous studies indicate a greater importance for intact IL-12/23 p40 expression than IL-12 p35 for immunity against Mycobacterium tuberculosis, suggesting a role for IL-23 in host defense. The effects of
Estrogen related receptors stimulate pyruvate dehydrogenase kinase isoform 4 (PDK4) gene expression.
Journal:J Biol Chem
PubMed ID:17079227
The pyruvate dehydrogenase complex (PDC) catalyzes the conversion of pyruvate to acetyl-CoA in mitochondria and is a key regulatory enzyme in the oxidation of glucose to acetyl-CoA. Phosphorylation of PDC by the pyruvate dehydrogenase kinases (PDK2 and PDK4) inhibits PDC activity. Expression of the PDK genes is elevated in diabetes
Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholipase A2.
Journal:J Biol Chem
PubMed ID:15863501
Human group III secreted phospholipase A(2) (sPLA(2)-III) consists of a central group III sPLA(2) domain flanked by unique N- and C-terminal domains. We found that the sPLA(2) domain alone was sufficient for its catalytic activity and for its prostaglandin E(2) (PGE(2))-generating functions in various cell types. In several if not